Promotie onderzoek

1. Stress-relieving: 3D printing personalized cortisol for patients with adrenal insufficiency
2. A novel delayed release hydrocortison formulation for patients with adrenal insufficiency
3. Feasibility study of 10 mg 3D printed systained release hydrocortisone 
4. Feasibility study of 3D printed delayed release hydrocortisone 
5. RCT of novel 3D printed hydrocortisone vs standard of care in adrenal insufficiency 

Naast het genotype zijn er andere factoren die van invloed zijn op de absorptie, distributie, metabolisme en excretie van medicijnen. Deze invloeden kunnen resulteren in een mismatch tussen fenotype en genotype. Het is dus belangrijk dat wij genotype kunnen suplementeren met een minimaal invasieve vorm van fenotypering. Doormiddel van cel representatieve Extracellulaire blaasjes in het bloed willen wij de expressie van pharmacogenen bepalen om personalized medicine te bevorderen  

Hospital expenditure of expensive drugs increases yearly. In addition, shortages are becoming more common. To assure access to healthcare and treatment in the future, sustainable use of expensive drugs is very important. This research aims to optimize treatment with regard to efficacy and safety, while aiming to reduce drug costs. 
 

The research focusses on several aspects related to reimbursement: factors influencing the time to reimbursement, measures to improve the time to reimbursement, differences in the clinical evidentiary requirements of oncology assessment, EMA versus HTA bodies and changes in economic evaluations of oncology drugs in time.
 

The research project aims to develop models for the prediction of disease duration in order to support personalized and cost-effective care of depression patients. Using these models, optimal treatment strategies will be analyzed. In this project, we also want to predict treatment resistant depression as a specific subgroup and conduct cost-effectiveness analyses of different psychotherapy strategies and quantify the impact of structural uncertainty and parameter uncertainty on the results of cost-effectiveness evaluations.